13 million Adults Gaining Access to RSV Vaccines

With over 13 million adults at increased risk in the United States, GSK plc announced that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of Respiratory Syncytial Virus (RSV) vaccines, including AREXVY in adults aged 50-59 who are at increased risk for severe RSV disease.

This action expands on ACIP’s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74.

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.

Tony Wood, Chief Scientific Officer, GSK, commented in a press release on April 16, 2025, “RSV can have a significant impact for those with underlying medical conditions. We look forward to helping protect more people with RSV vaccination.”

The ACIP recommendations will be forwarded for review and approval by the U.S. Centers for Disease Control and Prevention. Once approved, the final recommendations will be published to advise healthcare providers on the appropriate use of the vaccine and to inform insurance coverage.